Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: Systematic review and meta-analysis

Journal of Clinical Oncology

Volumn 25, Issue 34, 2007, Pages 5471-5489

  Robenshtok, Eyal ^a   Gafter Gvili, Anat ^a   Goldberg, Elad ^a   Weinberger, Miriam ^a   Yeshurun, Moshe ^a   Leibovici, Leonard ^a   Paul, Mical ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; IMMUNOMODULATING AGENT; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NYSTATIN; PLACEBO; POLYENE; POSACONAZOLE; VORICONAZOLE;

ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASPERGILLUS; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANDIDA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MORTALITY; MYCOSIS; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SURVIVAL RATE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 36849012946     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.3851     Document Type: Review

References (150)

1. Prentice HG, Kibbler CC, Prentice AG: Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 110:273-284, 2000
2. Pfaller MA, Pappas PG, Wingard JR: Invasive fungal pathogens: Current epidemiological trends. Clin Infect Dis 43:S3-S14, 2006 (suppl 1)
3. Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 32:358-366, 2001
4. Glasmacher A, Cornely OA, Orlopp K, et al: Caspofungin treatment in severely ill, immunocompromised patients: A case-documentation study of 118 patients. J Antimicrob Chemother 57:127-134, 2006
5. Herbrecht R, Denning DW, Patterson TF, et al: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415, 2002
6. van Gool R: The cost of treating systemic fungal infections. Drugs 61:49-56, 2001 (suppl 1)
7. Rinaldi MG: Problems in the diagnosis of invasive fungal diseases. Rev Infect Dis 13:493-495, 1991
8. Hughes WT, Armstrong D, Bodey GP, et al: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751, 2002
9. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Cytotherapy 3:41-54, 2001
10. Maertens J: Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 78:275-282, 2007
11. Bow EJ, Laverdiere M, Lussier N, et al: Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta analysis of randomized-controlled clinical trials. Cancer 94:3230-3246, 2002
12. Gøtzsche PC, Johansen HK: Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 314:1238-1244, 1997
13. Kanda Y, Yamamoto R, Chizuka A, et al: Prophylactic action of oral fluconazole against fungal infection in neutropenic patients: A meta-analysis of 16 randomized, controlled trials. Cancer 89:1611-1625, 2000
14. Glasmacher A, Prentice A, Gorschluter M, et al: Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients. J Clin Oncol 21:4615-4626, 2003
15. Jorgensen KJ, Gotzsche PC, Johansen HK: Voriconazole versus amphotericin B in cancer patients with neutropenia. Oxford, United Kingdom, Cochrane Library, CD004707, 2006
16. Vardakas KZ, Michalopoulos A, Falagas ME: Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: A meta-analysis of randomised-controlled trials. Br J Haematol 131:22-28, 2005
17. Gotzsche PC, Johansen HK: Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Oxford, United Kingdom, Cochrane Library, CD000026, 2002
18. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. http://www.cochrane.org/resources/handbook/
19. Ascioglu S, Rex JH, de Pauw B, et al: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 34:7-14, 2002
20. Cuttner J, Troy KM, Funaro L, et al: Clotrimazole treatment for prevention of oral candidiasis in patients with acute leukemia undergoing chemotherapy: Results of a double-blind study. Am J Med 81:771-774, 1986
21. Williams C, Whitehouse JM, Lister TA, et al: Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemia. Med Pediatr Oncol 3:275-280, 1977
22. Yeo E, Alvarado T, Fainstein V, et al: Prophylaxis of oropharyngeal candidiasis with clotrimazole. J Clin Oncol 3:1668-1671, 1985
23. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 327:557-560, 2003
24. Bucher HC, Guyatt GH, Griffith LE, et al: The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:683-691, 1997
25. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101, 1994
26. Perfect JR, Klotman ME, Gilbert CC, et al: Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 165:891-897, 1992
27. Riley DK, Pavia AT, Beatty PG, et al: The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 97:509-514, 1994
28. Kelsey SM, Goldman JM, McCann S, et al: Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 23:163-168, 1999
29. Tollemar J, Ringden O, Andersson S, et al: Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 12:577-582, 1993
30. Cornely OA, Bohme A, Vehreschild JJ, et al: Evaluating voriconazole (VCZ) as primary antifungal prophylaxis during induction chemotherapy for acute myelogenous leukemia (AML). Presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006
31. Bodey GP, Samonis G, Rolston K: Prophylaxis of candidiasis in cancer patients. Semin Oncol 17:24-28, 1990 (suppl 6)
32. Chandrasekar PH, Gatny CM: Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients: Bone Marrow Transplantation Team. Chemotherapy 40:136-143, 1994
33. Goodman JL, Winston DJ, Greenfield RA, et al: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845-851, 1992
34. Rotstein C, Bow EJ, Laverdiere M, et al: Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy - The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 28:331-340, 1999
35. Schaffner A, Schaffner M: Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 172:1035-1041, 1995
36. Slavin MA, Osborne B, Adams R, et al: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: A prospective, randomized, double-blind study. J Infect Dis 171:1545-1552, 1995
37. Winston DJ, Chandrasekar PH, Lazarus HM, et al: Fluconazole prophylaxis of fungal infections in patients with acute leukemia: Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 118:495-503, 1993
38. Nucci M, Biasoli I, Akiti T, et al: A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 30:300-305, 2000
39. Menichetti F, Del Favero A, Martino P, et al: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial - GIMEMA Infection Program, Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 28:250-255, 1999
40. Benhamou E, Hartmann O, Nogues C, et al: Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. Bone Marrow Transplant 7:127-131, 1991
41. Brincker H: Prevention of mycosis in granulocytopenic patients with prophylactic ketoconazole treatment. Mykosen 26:242-247, 1983
42. Hansen RM, Reinerio N, Sohnle PG, et al: Ketoconazole in the prevention of candidiasis in patients with cancer: A prospective, randomized, controlled, double-blind study. Arch Intern Med 147:710-712, 1987
43. Palmblad J, Lonnqvist B, Carlsson B, et al: Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: More bacteraemias. J Intern Med 231:363-370, 1992
44. Kern W, Behre G, Rudolf T, et al: Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: Results of a prospective randomized phase III study - German AML Cooperative Group. Cancer 83:291-301, 1998
45. Walsh TL, Bachier C, Shaughnessy P, et al: Efficacy of fluconazole prophylaxis for autologous peripheral blood stem cell transplantation: results of a prospective, randomized, controlled, multicenter, open label study. Presented at the 46th American Society of Hematology Annual Meeting, San Diego, CA, December 4-7, 2004
46. Yamaçc K, Senol E, Haznedar R: Prophylactic use of fluconazole in neutropenic cancer patients. Postgrad Med J 71:284-286, 1995
47. Kaptan K, Ural AU, Cetin T, et al: Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia. J Infect Chemother 9:40-45, 2003
48. Estey E, Maksymiuk A, Smith T, et al: Infection prophylaxis in acute leukemia: Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. Arch Intern Med 144:1562-1568, 1984
49. Penack O, Schwartz S, Martus P, et al: Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: Results from a randomized, single-center trial. Ann Oncol 17:1306-1312, 2006
50. Akiyama H, Mori S, Tanikawa S, et al: Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies. Mycoses 36:373-378, 1993
51. Brammer KW: Management of fungal infection in neutropenic patients with fluconazole. Haematol Blood Transfus 33:546-550, 1990
52. Egger T, Gratwohl A, Tichelli A, et al: Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients: A prospective, randomized, single-center study. Support Care Cancer 3:139-146, 1995
53. Ellis ME, Clink H, Ernst P, et al: Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 13:3-11, 1994
54. Menichetti F, Del Favero A, Martino P, et al: Preventing fungal infection in neutropenic patients with acute leukemia: Fluconazole compared with oral amphotericin B. Ann Intern Med 120:913-918, 1994
55. Meunier F, Aoun M, Janssens M, et al: Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole vs oral amphotericin B. Drug Invest 3:258-265, 1991
56. Ninane J: A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies: Multicentre Study Group. Eur J Clin Microbiol Infect Dis 13:330-337, 1994
57. Philpott-Howard JN, Wade JJ, Mufti GJ, et al: Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia: Multicentre Study Group. J Antimicrob Chemother 31:973-984, 1993
58. Rozenberg-Arska M, Dekker AW, Branger J, et al: A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. J Antimicrob Chemother 27:369-376, 1991
59. Van Delden C, Lew DP, Chapuis B, et al: Antifungal prophylaxis in severely neutropenic patients: How much fluconazole is necessary? Clin Microbiol Infect 1:24-30, 1995
60. Young GA, Bosly A, Gibbs DL, et al: A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia: Antifungal Prophylaxis Study Group. Eur J Cancer 35:1208-1213, 1999
61. Donnelly JP, Starke ID, Galton DA, et al: Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. J Hosp Infect 5:83-91, 1984
62. Hann IM, Prentice HG, Corringham R, et al: Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1:826-829, 1982
63. Jones PG, Kauffman CA, McAuliffe LS, et al: Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients. Arch Intern Med 144:549-551, 1984
64. Shepp DH, Klosterman A, Siegel MS, et al: Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis 152:1257-1263, 1985
65. Vogler WR, Malcom LG, Winton EF: A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients. Cancer Invest 5:267-273, 1987
66. Meunier-Carpentier F, Cruciani M, Klastersky J: Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. Eur J Cancer Clin Oncol 19:43-48, 1983
67. Boogaerts M, Maertens J, van Hoof A, et al: Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 48:97-103, 2001
68. Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al: Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 44:1887-1893, 2000
69. Lass-Flörl C, Gunsilius E, Gastl G, et al: Fungal colonization in neutropenic patients: A randomized study comparing itraconazole solution and amphotericin B solution. Ann Hematol 82:565-569, 2003
70. Vreugdenhil G, Van Dijke BJ, Donnelly JP, et al: Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy: A double blind, placebo controlled study. Leuk Lymphoma 11:353-358, 1993
71. Annaloro C, Oriana A, Tagliaferri E, et al: Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica 80:512-517, 1995
72. Huijgens PC, Simoons-Smit AM, van Loenen AC, et al: Fluconazole versus itraconazole for the prevention of fungal infections in haematooncology. J Clin Pathol 52:376-380, 1999
73. Glasmacher A, Cornely O, Ullmann AJ, et al: An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 57:317-325, 2006
74. Marr KA, Crippa F, Leisenring W, et al: Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103:1527-1533, 2004
75. Morgenstern GR, Prentice AG, Prentice HG, et al: A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies: U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 105:901-911, 1999
76. Oren I, Rowe JM, Sprecher H, et al: A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 38:127-134, 2006
77. Winston DJ, Maziarz RT, Chandrasekar PH, et al: Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: A multicenter, randomized trial. Ann Intern Med 138:705-713, 2003
78. Bodey GP, Anaissie EJ, Elting LS, et al: Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 73:2099-2106, 1994
79. Koh LP, Kurup A, Goh YT, et al: Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 71:260-267, 2002
80. Wolff SN, Fay J, Stevens D, et al: Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: A study of the North American Marrow Transplant Group. Bone Marrow Transplant 25:853-859, 2000
81. Cornely OA, Maertens J, Winston DJ, et al: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348-359, 2007
82. Ullmann AJ, Lipton JH, Vesole DH, et al: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335-347, 2007
83. MacMillan ML, Goodman JL, DeFor TE, et al: Fluconazole to prevent yeast infections in bone marrow transplantation patients: A randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 112:369-379, 2002
84. Mattiuzzi GN, Alvarado G, Giles FJ, et al: Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 50:143-147, 2006
85. Mattiuzzi GN, Estey E, Raad I, et al: Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97:450-456, 2003
86. Mattiuzzi GN, Alvarado G, Kantarjian HM, et al: Intravenous Voriconazole (IV-VORI) prevents invasive fungal infections (IFI) in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Presented at the 46th American Society of Hematology Annual Meeting, San Diego, CA, December 4-7, 2004
87. Hiemenz J, Cagnoni P, Simpson D, et al: Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 49:1331-1336, 2005
88. van Burik JA, Ratanatharathorn V, Stepan DE, et al: Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39:1407-1416, 2004
89. Timmers GJ, Zweegman S, Simoons-Smit AM, et al: Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: Data of a prematurely stopped clinical trial. Bone Marrow Transplant 25:879-884, 2000
90. Buchanan AG, Riben PD, Rayner EN, et al: Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: Correlation of colonization and clinical outcome. Clin Invest Med 8:139-147, 1985
91. Schwartz S, Behre G, Heinemann V, et al: Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial. Blood 93:3654-3661, 1999
92. Uhlenbrock S, Zimmermann M, Fegeler W, et al: Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: Interim analysis of a prospective study. Mycoses 44:455-463, 2001
93. Urabe A, Takaku F, Mizoguchi H, et al: Prophylactic and therapeutic effects of oral administration of amphotericin B in mycosis associated with hematologic diseases: Study Group of Mycosis in Hematologic Disease. Jpn J Antibiot 43:116-130, 1990
94. Akiyama H, Mori S, Tanikawa S, et al: Prevention of invasive fungal infection during chemotherapy-induced neutropenia in patients with acute leukemia. Kansenshogaku Zasshi 68:327-331, 1994
95. Prentice AG, Bradford GR: Prophylaxis of fungal infections with itraconazole during remission-induction therapy. Mycoses 32:96-102, 1989 (suppl 1)
96. Benjamin DK Jr, Driscoll T, Seibel NL, et al: Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 50:632-638, 2006
97. Grigg AP, Brown M, Roberts AW, et al: A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation. Bone Marrow Transplant 34:447-453, 2004
98. Toubai T, Tanaka J, Fujisawa F, et al: Effect of prophylaxis against mycosis in patients with hematological malignancy disease: Efficacy of dosage of itraconazole [in Japanese]. Jpn J Antibiot 56:61-65, 2003
99. Schmitt C, Perel Y, Harousseau JL, et al: Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis. Antimicrob Agents Chemother 45:1561-1564, 2001
100. Goranov S, Spasov E, Grudeva-Popova J, et al: Antifungal prophylaxis with low doses fluconazole in patients with hematological malignancies. Folia Med (Plovdiv) 41:68-72, 1999
101. Glasmacher A, Hahn C, Molitor E, et al: Itraconazole through concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 42:591-600, 1999
102. Takatsuka H, Takemoto Y, Okamoto T, et al: Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy. Drugs Exp Clin Res 25:193-200, 1999
103. Mücke R, Kaben U, Libera T, et al: Fluconazole prophylaxis in patients with head and neck tumours undergoing radiation and radiochemotherapy. Mycoses 41:421-423, 1998
104. van Burik JH, Leisenring W, Myerson D, et al: The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: An autopsy study of 355 patients. Medicine (Baltimore) 77:246-254, 1998
105. Lamy T, Bernard M, Courtois A, et al: Prophylactic use of itraconazole for the prevention of invasive pulmonary aspergillosis in high risk neutropenic patients. Leuk Lymphoma 30:163-174, 1998
106. Böhme A, Just-Nubling G, Bergmann L, et al: Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J Antimicrob Chemother 38:953-961, 1996
107. Ehninger G, Schuler HK, Sarnow E: Fluconazole in the prophylaxis of fungal infection after bone marrow transplantation. Mycoses 39:259-263, 1996
108. Carreras E, Batlle M, Redondo M, et al: Intravenous amphotericin B as prevention of deep mycoses in allogeneic bone marrow transplantation [in Spanish]. Med Clin (Barc) 103:761-765, 1994
109. Cáp J, Mojzesova A, Kayserova E, et al: Fluconazole in children: First experience with prophylaxis in chemotherapy-induced neutropenia in pediatric patients with cancer. Chemotherapy 39:438-442, 1993
110. Sajben P, Minarik T, Tomasik E, et al: Fluconazole plus ofloxacin in prophylaxis of infections in patients with acute leukemia: A comparative study. Support Care Cancer 1:214-216, 1993
111. Kimura I, Kuramoto J, Yahata Y, et al: A co-operative study on prophylactic effect of oral administration of high-dose amphotericin B syrup for systemic fungal infection in patients with hematological neoplasms: Chugoku-Shikoku Study Group of Mycosis with Hematologic Disease [in Japanese]. Gan To Kagaku Ryoho 17:1027-1032, 1990
112. Quintiliani R, Owens NJ, Quercia RA, et al: Treatment and prevention of oropharyngeal candidiasis. Am J Med 77:44-48, 1984
113. Kauffman CA, Jones PG, Bergman AG, et al: Effect of prophylactic ketoconazole and nystatin on fungal flora. Mykosen 27:165-172, 1984
114. Mattiuzzi GN, Kantarjian H, Faderl S, et al: Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100:581-589, 2004
115. Karthaus M, Doellmann T, Klimasch T, et al: Intensive intravenous amphotericin B for prophylaxis of systemic fungal infections: Results of a prospective controlled pilot study in acute leukemia patients. Chemotherapy 46:293-302, 2000
116. Tollemar J, Hockerstedt K, Ericzon BG, et al: Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: Results of two randomized double-blind studies. Transplant Proc 26:1833, 1994
117. Laverdière M, Rotstein C, Bow EJ, et al: Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients: The Canadian Fluconazole Study. J Antimicrob Chemother 46:1001-1008, 2000
118. Groll AH, Just-Nuebling G, Kurz M, et al: Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. J Antimicrob Chemother 40: 855-862, 1997
119. Tollemar J, Ringden O, Andersson S, et al: Prophylactic use of liposomal amphotericin B (Am-Bisome) against fungal infections: A randomized trial in bone marrow transplant recipients. Transplant Proc 25:1495-1497, 1993
120. Elad S, Wexler A, Garfunkel AA, et al: Oral candidiasis prevention in transplantation patients: A comparative study. Clin Transplant 20:318-324, 2006
121. Alexander BD, Dodds Ashley ES, Addison RM, et al: Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 8:13-20, 2006
122. Epstein JB, Truelove EL, Hanson-Huggins K, et al: Topical polyene antifungals in hematopoietic cell transplant patients: Tolerability and efficacy. Support Care Cancer 12:517-525, 2004
123. Erjavec Z, Woolthuis GM, de Vries-Hospers HG, et al: Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 16:364-368, 1997
124. Yamada T, Dan K, Nomura T: Prevention of bacterial and fungal infections in acute leukemia patients: A new and potent combination of oral norfloxacin and amphotericin B. Intern Med 32:710-715, 1993
125. Beyer J, Barzen G, Risse G, et al: Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 37:1367-1369, 1993
126. Myers SE, Devine SM, Topper RL, et al: A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma 8:229-233, 1992
127. Suda T, Omine M, Tsuchiya J, et al: A co-operative study on prophylaxis of fungal infection in patients with hematological diseases: Prophylactic effect of oral administration of amphotericin B (author's transl). Rinsho Ketsueki 21:195-199, 1980
128. Charak BS, Parikh PM, Banavali SD, et al: Comparison of clotrimazole with nystatin in preventing oral candidiasis in neutropaenic patients. Indian J Med Res 88:416-420, 1988
129. Brincker H: Prophylactic treatment with miconazole in patients highly predisposed to fungal infection: A placebo-controlled double-blind study. Acta Med Scand 204:123-128, 1978
130. Trenschel R, Peceny R, Runde V, et al: Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination. Bone Marrow Transplant 26:993-997, 2000
131. Goldstone AH, O'Driscoll A: Early AmBisome in febrile neutropenia in patients with haematological disorders. Bone Marrow Transplant 14:S15-S17, 1994 (suppl 5)
132. Wingard JR, Vaughan WP, Braine HG, et al: Prevention of fungal sepsis in patients with prolonged neutropenia: A randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 83:1103-1110, 1987
133. Fanci R, Campisi E, Faggi E, et al: Fungal infections in hematological neoplastic disease: The possibility of chemoprophylaxis. Chemioterapia 3:310-315, 1984
134. Mitrokhin SD: Itraconazole (Orungal) in the treatment of mycotic infections in oncologic patients[in LANGUAGE]. Antibiot Khimioter 48:16-21, 2003
135. Epstein JB, Vickars L, Spinelli J, et al: Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg Oral Med Oral Pathol 73:682-689, 1992
136. Krüger W, Stockschlader M, Sobottka I, et al: Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation. Leuk Lymphoma 24:491-499, 1997
137. Ellis ME, Halim MA, Spence D, et al: Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever: Preliminary observations from a pilot, exploratory study. J Infect 30:141-146, 1995
138. van't Wout JW: Itraconazole in neutropenic patients. Chemotherapy 38:23-26, 1992 (suppl 1)
139. Schaison G, Baruchel A, Arlet G: Prevention of gram-positive and Candida albicans infections using teicoplanin and fluconazole: A randomized study in neutropenic children. Br J Haematol 76:24-26, 1990 (suppl 2)
140. Prentice AG, Warnock DW, Johnson SA, et al: Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother 36:657-663, 1995
141. Bradford CR, Prentice AG, Warnock DW, et al: Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. J Antimicrob Chemother 28:555-560, 1991
142. Ellis ME, Qadri SM, Spence D, et al: The effect of fluconazole as prophylaxis for neutropenic patients on the isolation of Candida spp. from surveillance cultures. J Antimicrob Chemother 33: 1223-1228, 1994
143. Chandrasekar PH, Gatny CM: The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients: Bone Marrow Transplantation Team. J Antimicrob Chemother 33:309-318, 1994
144. Caselli D, Arico M, Michelone G, et al: Antifungal chemoprophylaxis in cancer children: A prospective randomized controlled study. Microbiologica 13:347-351, 1990
145. Scrimgeour E, Anderson JD: Ketoconazole prophylaxis in patients with solid tumours receiving aggressive immunosuppressive therapy: An open randomized comparison between 200 mg/d and 400 mg/d doses. S Afr Med J 67:1044-1045, 1985
146. Samonis G, Rolston K, Karl C, et al: Prophylaxis of oropharyngeal candidiasis with fluconazole. Rev Infect Dis 12:S369-S3673, 1990 (suppl 3)
147. Wingard JR: Design issues in a prospective randomized double-blind trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. Clin Infect Dis 15:S176-S180, 2004 (suppl 4)
148. Voriconazole versus itraconazole in primary prophylaxis of IFI in subjects with HSCT. ClinicalTrial. gov Identifier NCT00289991. http://www.clinical-trial. gov/ct/show/NCT00289991?order=1
149. Glasmacher A, Prentice A: Current experience with itraconazole in neutropenic patients: A concise overview of pharmacological properties and use in prophylactic and empirical antifungal therapy. Clin Microbiol Infect 12:84-90, 2006 (suppl 7)
150. Martino R, Viscoli C: Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 132:138-154, 2006